Yes at these levels PEB has 100m revenue - the stated 5-year goal - priced in. It's scary. But that's based on 10% market penetration with one product. If Cxbladder is really that good, then 80% market penetration or more are possible. Add to that the other products and you'll realize that there is still a lot of upside. Just think how much the product portfolio would be worth in the hands of Roche Diagnostics who know how to play the system top to bottom. Then think how much it would be worth to Roche Diagnostics and that's your price target.